Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q3 2023 · 10-Q
Revenue—
Net Income-$278.49K-$278.49KN/M vs Q3 2022 EPS Diluted$0.00$0.00— vs Q3 2022 Operating Cash Flowderived-$84,191N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Oct 28, 2025 · 759 d after period end